Loading stock data…
Loading stock data…
US$5.46
Get one email when RLMD crosses your level. Checked every 15 minutes during market hours.
▼ -0.75 (-12.08%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
30.0
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
-0.18
Bearish momentumMACD below its signal line (-0.11).
50-day average
6.72
Price belowShort-term trend reference.
200-day average
5.05
Price aboveLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for central nervous system disorders and oncology indications. Its primary efforts center on NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel designed for the treatment of non-muscle invasive bladder cancer, particularly in high-risk BCG-unresponsive and intermediate-risk patients, addressing significant unmet needs in urologic oncology. The company is also a…
www.relmada.com4 strong buy · 7 buy · 1 hold · 0 sell · 0 strong sell (12 analysts, 2026-07-01)
4 strong buy · 6 buy · 1 hold · 0 sell · 0 strong sell (11 analysts, 2026-06-01)
4 strong buy · 6 buy · 1 hold · 0 sell · 0 strong sell (11 analysts, 2026-05-01)
4 strong buy · 6 buy · 1 hold · 0 sell · 0 strong sell (11 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-03-19 | -0.14 | -0.29 | ✗ Miss |
| 2026-01-20 | 0.88 | 0.89 | ✓ Beat |
| 2025-11-13 | -0.04 | -0.3 | ✗ Miss |
| 2025-05-12 | -0.31 | -0.58 | ✗ Miss |
| 2025-03-27 | -0.7 | -0.62 | ✓ Beat |
| 2024-11-07 | -0.64 | -0.72 | ✗ Miss |
| 2024-08-07 | -0.83 | -0.59 | ✓ Beat |
| 2024-05-08 | -0.86 | -0.72 | ✓ Beat |
Companies in the same industry, via Finnhub